LifeMD, Inc. (NASDAQ:LFMD) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance, with significant revenue and EBITDA growth, despite a decline in gross margin. The Q&A session highlighted positive partnerships and insurance integration, though some responses were vague. The guidance remains optimistic, and new service offerings in mental and women's health, though small, are included. The lack of shareholder return plans is a minor negative, but overall, the company's strategic initiatives and financial improvements suggest a positive stock price movement.
Key Financial Performance
Total Revenues $65.7 million, an increase of 49% year-over-year.
Core Telehealth Revenue Grew by 70% versus the prior year.
Telehealth Adjusted EBITDA $5.3 million, a dramatic improvement from a loss of $1.3 million in the same period last year, representing a $6.6 million increase year-over-year.
Active Subscribers Increased 22% year-over-year to over 290,000.
WorkSimpli Active Subscribers Declined by 5% to 158,000.
WorkSimpli Adjusted EBITDA Exceeding $3 million for the quarter.
Gross Margin 86.8%, a decline of 270 basis points versus the prior year due to changes in revenue mix and temporary changes in pharmacy mix.
Gross Profit $57.1 million, an increase of 44% from the year-ago period.
GAAP Net Income $608,000 or $0.01 per diluted share, compared to a GAAP net loss of $7.5 million or a loss of $0.19 per share in the first quarter of 2024.
Adjusted EBITDA $8.7 million for the first quarter, compared with $0.1 million in the year-ago period.
Cash at Quarter End $34.4 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Men's Hormone Therapy Offering: Recent launch of men’s hormone therapy offering contributing to revenue growth.
LifeMDPlus: Upcoming launch of LifeMDPlus, an affordable monthly membership providing 24x7 access to synchronous care and other services.
Women's Health Program: Launch of a cash-pay, subscription-based women’s health program within 90 days, focusing on comprehensive lab testing and virtual visits.
Behavioral Health Services: Imminent entry into behavioral health with a full suite of tele-psychiatry services.
Medicare Fee-for-Service: Acceptance of fee-for-service Medicare, expanding coverage to over 21 million beneficiaries across 26 states, aiming for 49 states.
Partnerships with LillyDirect and NovoCare: Strategic collaborations to improve access to GLP-1 medications for weight management patients.
Telehealth Revenue Growth: Core Telehealth revenue grew by 70% year-over-year, with adjusted EBITDA reaching $5.3 million.
Active Subscribers: Active Telehealth subscribers increased by 22% year-over-year to over 290,000.
Gross Margin: Gross margin for Q1 was 86.8%, a decline of 270 basis points year-over-year but an increase of 150 basis points sequentially.
Expansion into New Verticals: Entering women's health and behavioral health markets, diversifying revenue streams.
Integrated Care Model: Leveraging a fully-integrated platform for continuity in care, enhancing patient experience.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: LifeMD's acceptance of fee-for-service Medicare opens a significant market but also presents regulatory challenges as they navigate compliance with Medicare regulations.
Competitive Pressures: LifeMD faces competitive pressures in the virtual care market, particularly as they expand into high-demand verticals like women's health and behavioral health, where established players may pose challenges.
Supply Chain Challenges: The company may encounter supply chain challenges related to the distribution of medications and healthcare products, especially as they expand their pharmacy benefits infrastructure.
Economic Factors: Economic factors, including potential changes in healthcare funding and reimbursement rates, could impact LifeMD's revenue and profitability, particularly in their Medicare initiatives.
Market Penetration Risks: As LifeMD expands its services to new verticals, there is a risk of not achieving the expected market penetration, which could affect revenue growth.
Technology Integration Risks: The integration of new technologies and partnerships, such as those with GLP-1 manufacturers, carries risks related to operational execution and patient adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core Telehealth Revenue Growth: Revenue grew 70% year-over-year, driven largely by strength in the weight management program.
Telehealth Adjusted EBITDA: Reached $5.3 million, a significant improvement from a loss of $1.3 million in the same period last year.
Expansion of RexMD: Continues to expand beyond sexual health into weight management, behavioral health, insomnia, and hormone replacement therapy.
Launch of LifeMDPlus: Planned introduction of LifeMDPlus to 180,000 active RexMD patients, offering 24x7 access to synchronous care.
Strategic Collaborations: Established partnerships with LillyDirect and NovoCare to improve access to GLP-1 medications for weight management patients.
Entry into Women's Health and Behavioral Health: Launching a cash-pay, subscription-based women’s health program and tele-psychiatry services.
2025 Total Revenue Guidance: Revised guidance for total revenues is in the range of $268 million to $275 million.
Telehealth Revenue Guidance: Telehealth revenue is projected to be in the range of $208 million to $213 million.
Consolidated Adjusted EBITDA Guidance: Revised guidance for consolidated adjusted EBITDA is in the range of $31 million to $33 million.
Telehealth Adjusted EBITDA Guidance: Telehealth adjusted EBITDA is expected to be at least $21 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: LifeMD has not announced any share buyback program or dividend program during this earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk a little bit about your relationships with Lilly and Novo? Specifically, can you talk about the pricing for each of those products? Is it like a revenue share on a per month basis?
A:Our relationship with both Lilly and Novo enables us to integrate our care offerings and streamline access to those medications for patients. The price that patients pay is the same as elsewhere, with no discounts or compensation from the drug manufacturers. We will have different pricing options based on care membership length and may run discounts and promotions.
Q:Can you talk about the role of insurance in your view?
A:At LifeMD, we feel the insurance component is very important. We’ve invested in building a platform for accepting insurance programs, which we believe makes care more accessible and drives retention. We will continue to have cash-pay offerings, but we think insurance is crucial for long-term success.
Q:Could you give us an update on your launch of your compounding pharmacy?
A:Our compounding pharmacy is on track to be licensed this summer and in most states by the end of the year. We are scaling our mail-order pharmacy, averaging close to 1,000 prescriptions a day, which has positively impacted our bottom line.
Q:Does your 2025 guidance include contributions from mental health and women’s health?
A:Yes, it does, but the contributions are small, around $5 million combined. Female health is already generating revenue, while mental health will contribute more in the back half of the year.
Q:How much of the positive guidance revision for 2025 is related to the Wegovy, NovoCare pharmacy announcement?
A:None of it is related to that announcement; it’s all based on our Q1 performance. The partnerships provide another avenue for treatment but do not change our guidance.
Q:Can you tell us about a patient seeking weight management, how is he going to choose one of the two medications?
A:The patient’s choice of medication does not affect LifeMD’s revenue. Patients may choose based on price or delivery mechanism, and the provider will recommend based on clinical presentation.
Q:Does LifeMD plan to continue to offer compounded GLP-1 in the coming years?
A:LifeMD does not compound GLP-1 medications. We focus on helping patients access branded therapies, and we may send prescriptions to compounding pharmacies if necessary.
Q:Is your guidance for Telehealth being conservative or are there headwinds anticipated?
A:It’s not about headwinds; it’s about timing in revenue. We expect some seasonal softness in Q2, but overall growth year-on-year is strong.
Q:Could you talk about the challenges faced by WorkSimpli this quarter?
A:There are no significant challenges. The business is a non-core asset, and we aim to maximize cash flow rather than topline growth. Subscriber numbers are down, but revenue is up due to a shift to higher value customers.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific impact of the Wegovy and NovoCare announcement on their guidance for 2025, stating it was too early to incorporate that into their guidance. Additionally, there was vague language around the pricing structure for their weight management program, indicating it would be similar to current charges but lacking specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO afternoon
Core Telehealth
LabCorp National
LifeMDPlus care
LifeMDPlus membership
LillyDirect NovoCare
LillyDirect access
National Pharmacy
NovoCare LillyDirect
Pharmacy level
RexMD brand
RexMD patient
Telehealth WorkSimpli
Telehealth date
Telehealth improvement
Telehealth result
Telehealth strength
Transcript afternoon
care model
cash today
collaboration LillyDirect
consults
core Telehealth
end Medicare
health focus
irlifemdcom progress
loss period
measure Telehealth
membership access
model RexMD
offering RexMD
offering Telehealth
outperformance Telehealth
partnership
provider network
result Justin
revenue
subscription
vertical
LFMD Transcript
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call reveals several concerns: a decline in weight management revenue, reduced financial guidance, and margin pressures due to shifts in business mix. Although there is optimism for 2026 and some positive developments like insurance coverage and new product lines, these are long-term prospects. The immediate financial outlook is weakened by the revised guidance and margin erosion, leading to a likely negative market reaction in the short term.
LifeMD, Inc. (LFMD) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong telehealth revenue growth and strategic partnerships are positive, but concerns arise from fluctuating customer acquisition costs and guidance reduction related to the RexMD business. The Q&A reveals management's evasiveness on certain metrics, which can create uncertainty. Despite positive new initiatives and raised guidance for 2025, the immediate impact is tempered by operational challenges and lack of clear answers on key metrics, resulting in a neutral sentiment.
LifeMD, Inc. (NASDAQ:LFMD) Q1 2025 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance, with significant revenue and EBITDA growth, despite a decline in gross margin. The Q&A session highlighted positive partnerships and insurance integration, though some responses were vague. The guidance remains optimistic, and new service offerings in mental and women's health, though small, are included. The lack of shareholder return plans is a minor negative, but overall, the company's strategic initiatives and financial improvements suggest a positive stock price movement.
Earnings call transcript: LifeMD Q1 2025 earnings beat expectations, stock rises
Positive5-6
The earnings call reveals strong financial performance with a 49% revenue increase and positive GAAP net income, a first for the company. Despite a decline in gross margin, sequential improvement was noted. The Q&A highlighted strong retention revenue and operational efficiency. However, lack of shareholder return plans and uncertainties in pricing and guidance details slightly temper enthusiasm. Overall, the positive financial performance and optimistic guidance suggest a likely stock price increase, warranting a 'Positive' rating.
LFMD Slides
LFMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
